08:30–09:30Industry Symposium

09:30–09:45Scientific Posters and Coffee

09:45–11:00Access to Long Acting Prevention for Key Populations in Low and Middle
Income Countries (LMICs): Making it Work
In collaboration with the International AIDS Society (IAS)

Chairs:Anton Pozniak, Chelsea & Westminster Hospital, London, UK;
Immediate Past-President, International AIDS Society
Claudia Cortes, University of Chile, Santiago, Chile; IAS Governing Council

09:45–09:50Introduction and aims
Anton Pozniak, and Claudia Cortes

09:50–10:02Landscape, service delivery, and pathways to affordability and access
Mitchell Warren, AIDS Vaccine Advocacy Coalition (AVAC), New York, NY, USA

10:02–10:14Examples and insights from Asia
Nittaya Phanuphak, Institute of HIV Research and Innovation, Bangkok, Thailand

10:14–10:26Examples and insights from Latin America
Beatriz Grinsztejn, FioCruz, Rio de Janeiro, Brazil

10:26–10:38Examples and insights from Africa
Kenly Sikwese, AfroCAB, Lusaka, Zambia

10:38–10:55Panel discussion and Q&A
All joined by Cissy Kityo, Joint Clinical Research Centre, Kampala, Uganda

10:55–11:00Summary and Close
Chairs

11:00–11:45HIV Clinical Challenges (II)
11:00–11:15Older people with well-controlled HIV have similar antibody and higher T-cell
responses after vaccination against SARS-CoV-2 compared to demographically
and lifestyle-comparable people without HIV
Myrthe Verburgh, Infectious Diseases, Amsterdam UMC, University of
Amsterdam, Amsterdam, Netherlands

11:15–11:30External validation of the Dat’AIDS score for predicting 5-year mortality among
elderly patients living with HIV in the Swiss HIV Cohort Study
Maxime Hentzien, HIV/AIDS Research Unit, Geneva University Hospitals,
Geneva, Switzerland

11:30–11:45COCOVIH study: impact of comorbidities on the over-mortality of people
living with HIV
François Prevoteau Du Clary, Centre de Santé Sexuelle, La Grave Hospital,
University Hospital Toulouse, Toulouse, France

11:45–12:30Lock Lecture
HIV Glasgow is honoured to have been chosen by the Royal College of Physicians and
Surgeons of Glasgow to present the Lock Lecture as part of the Scientific Programme

11:45–11:50Introduction

11:50–12:20PrEP vs PEP Interface: Where are We Now?
Sheena McCormack, Clinical Epidemiology, Imperial College London, UK

12:20–12:30Q&A
All

12:30–13:45Scientific Posters and Lunch

12:45–13:45Industry Symposium

13:45–15:00Response to Emerging Problems
In collaboration with the European AIDS Clinical Society (EACS)

Chairs:Tristan Barber, HIV Medicine, Ian Charleson Day Centre, Royal Free
Hospital, London, UK; and Chair, EACS Young Investigators (YING)
Georg Behrens, Department for Clinical Immunology and Rheumatology
Hannover Medical School, Hannover, Germany; and Chair,
EACS Guidelines Group

13:45–13:50Welcome and Introductions
Chairs

13:50–14:05Unified support framework to support HIV cascade of care for displaced
persons in Europe
Marta Vasylyev, Infectious Diseases, Astar Medical Center, Lviv, Ukraine; and
Co-chair, WAVE

14:05–14:20HIV Clinics and people living with HIV in times of epidemics: impact of
COVID-19 and MonkeyPox
Casper Rokx, HIV/Infectious Diseases, Erasmus University Medical Center, Rotterdam, The Netherlands; and YING Scientific Committee

14:20–14:352022 update EACS Guidelines
Juan Ambrosioni, HIV/AIDS Unit and Infectious Disease Service, Hospital
Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain; and Co-ordinator,
EACS Guidelines

14:35–14:55Panel discussion and Q&A
All

14:55–15:00Wrap up and close

15:00–16:00Novel Therapeutics
15:00–15:25HIV and COVID-19 drug development: lessons learned for the next pandemic
Daniel Kuritzkes, Division of Infectious Diseases at Brigham and
Women’s Hospital, Boston, MA, USA

15:25–15:45bNABS for HIV
Marina Caskey, Laboratory of Molecular Immunology, The Rockefeller University,
New York, NY, USA

15:45–16:00VH3810109 (N6LS) reduces viremia across a range of doses in ART-naive
adults living with HIV: proof of concept achieved in the phase IIa
BANNER (207959, NCT04871113) study
Peter Leone, Clinical Development, ViiV Healthcare, Durham, NC, USA

16:00–17:15HIV Current Case Challenges: Interactive case study session
In collaboration with the International Antiviral Society-USA (IAS-USA)

Chairs:Roy Gulick, Infectious Diseases, Weill Cornell Medicine, New York, NY, USA
Chloe Orkin, Queen Mary University of London and Barts Health NHS
Trust, London, UK

16:00–16:05Welcome and Introductions
Chairs

16:05–16:25Heavily treatment-experienced case
Alexandra Calmy, Geneva, Switzerland

16:25–16:45HPV-related case
Deborah Konopnicki, Department of Infectious Diseases, Saint-Pierre University Hospital,  and Université Libre de Bruxelles, Brussels, Belgium

16:45–17:05HIV and COVID-related case
Jose Arribas, La Paz Hospital, Madrid, Spain

17:05–17:15Key learnings summary and close
Chairs

17:15–17:30Scientific Posters and Coffee

17:30–18:30Industry Symposium